#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Iatrogenic injury of the gastrointestinal tract


Authors: Kateřina Kamarádová 1,2
Authors‘ workplace: Fingerlandův ústav patologie, Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Hradec Králové, Hradec Králové 1;  Unilabs Pathology k. s., Laboratoř Praha, Praha 2
Published in: Čes.-slov. Patol., 62, 2026, No. 3, p. 137-162
Category: Reviews Article

Overview

Iatrogenic or drug-induced injury to the gastrointestinal tract (GIT) is relatively common and continues to increase with the introduction of new treatment methods, including biologic and targeted therapies. Identification of drug-induced changes is often very difficult and not always identified by pathologists. The mucosa of the gastrointestinal tract can be injured by a variety of drugs including frequently used types as nonsteroidal anti-inflammatory drugs as well as drugs with narrow spectrum of indication as chemotherapy or radiation therapy. Unfortunately, there is a limited spectrum of mucosal reactions and histological changes can be often nonspecific or overlap with the morphology of other histologically defined diseases. Moreover, a single drug or group of drugs can induce different histological changes in the mucosa, including their combinations; conversely, a single morphological pattern may be shared by multiple drugs. The aim of this text is to explore the patterns of drug-induced changes in the gastrointestinal tract with focus on the esophagus, stomach, small and large bowel but also highlight certain morphological patterns of selected medication classes. The role of the pathologist is to consider the possibility of drug-induced injury but also rule out other primary or underlying disease. Therefore, careful clinical correlation including confirmation of the medication history and causal relationship is essential.

Keywords:

side effects – Gastrointestinal tract – iatrogenic – drug-induced injury – histopathology of drug-induced changes


Sources

1. Gordon IO, Konda V, Noffsinger AE. Drug -⁠ -induced Injury of the Gastrointestinal Tract. Surg Pathol Clin 2010;3(2):361-393.

2. Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 2007;38(4):527-536.

3. Angerer L, Zauner T, Langer R. Rare non-neoplastic gastrointestinal diseases-drugs and bugs. Seltene nichtneoplastische gastrointestinale Erkrankungen –⁠ Medikamente und Parasiten. Pathologie (Heidelb) 2026;47(Suppl 1):51-58.

 4. Kim JW, Kim BG, Kim SH, et al. Histomorphological and Immunophenotypic Features of Pill-Induced Esophagitis. PLoS One 2015;10(6):e0128110.

5. De Petris G, Caldero SG, Chen L, et al. Histopathological changes in the gastrointestinal tract due to medications: an update for the surgical pathologist (part II of II). Int J Surg Pathol 2014;22(3):202-211.

 6. Saleem F, Sharma A. Drug-Induced Esophagitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 20, 2023.

7. Shih AR, Misdraji J. Drug-induced pathology of the upper gastrointestinal tract. Diag Histopathol 2017; 23 (2): 84-95

8. Noffsinger AE. Update on esophagitis: controversial and underdiagnosed causes. Arch Pathol Lab Med 2009;133(7):1087-1095.

9. Collins MH, Martin LJ, Alexander ES et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus 2017; 30(3):1-8.

10. Scalese G, Ribichini E, Covotta F et al. Drug-Induced Versus Eosinophilic Esophagitis: A Challenging Case Report. Ann Case Report 2024; 9 : 1653.

11. Daum O, Kokošková B, Švajdler M. Morfologie gastroezofageálního refluxu. Cesk Patol 2016;52(1):15-22.

12. Daum O, Dubová M, Švajdler M. Patologická diagnostika nerefluxních ezofagitid. Cesk Patol 2016;52(1):23-30.

13. Bae HJ, Choe Y. Esophageal Mucosal Injuries From Drugs, Radiation, and Caustic Agents. Korean J Helicobacter Up Gastrointest Res 2025;25(2):126-133.

14. Shah J, Jena A, Shweta S, et al. Corrosive induced esophageal and gastric injury: Histopathological evaluation of surgically resected specimens over a decade in a tertiary care center. Indian J Pathol Microbiol 2024;67(2):379-384.

15. Hall AH, Jacquemin D, Henny D et al. Corrosive substances ingestion: a review. Crit Rev Toxicol 2019;49(8):637-669.

16. Carmack SW, Vemulapalli R, Spechler SJ, Genta RM. Esophagitis dissecans superficialis („sloughing esophagitis“): a clinicopathologic study of 12 cases. Am J Surg Pathol 2009;33(12):1789-1794.

17. Purdy JK, Appelman HD, McKenna BJ. Sloughing esophagitis is associated with chronic debilitation and medications that injure the esophageal mucosa. Mod Pathol 2012;25(5):767-775.

18. Hart PA, Romano RC, Moreira RK et al. Esophagitis Dissecans Superficialis: Clinical, Endoscopic, and Histologic Features. Dig Dis Sci 2015;60(7):2049-2057.

19. Karaaslan S, Qin L, Hissong E, Jessurun J. A reappraisal of oesophageal mucosal biopsy specimens showing sloughing. Histopathology 2025;87(4):598-605.

20. Ettel  mg, Gonzalez RS. Microscopic Esophageal Sloughing Is Not Specific to „Sloughing Esophagitis“. Am J Clin Pathol 2021;155(6):895 -⁠ 902.

21. Rubrecht A, Saulino D, Nasri E, et al. Sloughing Esophagitis in the Pediatric Age Group: Clinicopathologic Characteristics of 12 Cases. Pediatr Dev Pathol 2025;28(3):172-178.

22. Qasim A, Jyala A, Ghazanfar H, et al. Esophagitis Dissecans Superficialis: Unveiling the Enigmatic Entity of Esophageal Mucosal Sloughing. Cureus 2023;15(8):e43549.

23. Toya Y, Nakamura S, Tomita K, et al. Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics. J Gastroenterol Hepatol 2016;31(3):610-614.

24. Zhou Y, Dai Y, Lu L, Fu Z. Dabigatran-induced esophagitis: A case report. Medicine (Baltimore) 2020;99(17):e19890.

25. Zhou Y, Su Y, Li Z et al. Analysis of the clinical characteristics of dabigatran-induced oesophagitis. Eur J Hosp Pharm 2023;30(e1):e24-e28.

26. Rouphael C, Gordon IO, Thota PN. Lymphocytic esophagitis: Still an enigma a decade later. World J Gastroenterol 2017;23(6):949-956.

27. Pittman ME, Hissong E, Katz PO, Yantiss RK. Lymphocyte-predominant Esophagitis: A Distinct and Likely Immune-mediated Disorder Encompassing Lymphocytic and Lichenoid Esophagitis. Am J Surg Pathol 2020;44(2):198 -⁠ 205.

28. Coady LC, Sheahan K, Brown IS, et al. Esophageal lymphocytosis: exploring the knowns and unknowns of this pattern of esophageal injury. Expert Rev Gastroenterol Hepatol 2024;18(9):529-539.

29. Rubio CA, Sjödahl K, Lagergren J. Lymphocytic esophagitis: a histologic subset of chronic esophagitis. Am J Clin Pathol 2006;125(3):432-437.

30. Rubio CA, Ichiya T, Schmidt PT. Lymphocytic oesophagitis, eosinophilic oesophagitis and compound lymphocytic-eosinophilic oesophagitis I: histological and immunohistochemical findings. J Clin Pathol 2017;70(3):208 -⁠ 216.

31. Pittman ME. Lymphocytic Esophagitis: Current Understanding and Controversy. Am J Surg Pathol 2022;46(1):e55-e63.

32. Patil DT, Hammer S, Langer R, Yantiss RK. Lymphocytic esophagitis: an update on histologic diagnosis, endoscopic findings, and natural history. Ann N Y Acad Sci 2018;1434(1):185-191.

33. Rubio CA. Lymphocytic esophagitis updated. Ann N Y Acad Sci 2019;1445(1):3-4.

34. Varelas AI, Fürst S, Langner C. Mixed lymphocytic and collagenous inflammation of the entire gastrointestinal tract under therapy with serotonin and norepinephrine reuptake inhibitors. Virchows Arch 2022;481(5):779-783.

35. Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists‘ perspective. J Clin Pathol 2018;71(8):665-671.

36. Nelson KK, Clayton SB, Champeaux AL et al. Caustic Injury and Stricture of the Esophagus After Long-Term Phenytoin Use. ACG Case Rep J 2015;2(2):83-85.

37. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008;135(1):41 -⁠ 60.

38. Srivastava A, Lauwers GY. Pathology of non-infective gastritis. Histopathology 2007;50(1):15-29.

39. El-Zimaity H, Riddell RH. Beyond Helicobacter: dealing with other variants of gastritis-an algorithmic approach. Histopathology 2021;78(1):48-69.

40. Daum O, Daumová M, Švajdler M. Diferenciální diagnostika nenádorových onemocnění žaludku. Cesk Patol 2022;58(2):77-87.

41. Vieth M, Montgomery E. Medication-associated gastrointestinal tract injury. Virchows Arch 2017;470(3):245-266.

42. Jalving M, Koornstra JJ, Wesseling J et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24(9):1341-1348.

43. Zelter A, Fernández JL, Bilder C, et al. Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. Dig Dis Sci 2011;56(6):1743-1748.

44. Kővári B, El Naili R, Pereira DV, et al. Fundic gland polyps related to diverse aetiologies show subtle morphological differences: a multicentre retrospective study. Histopathology 2022;80(5):827-835. 45. De Petris G, Gatius Caldero S, Chen L, et al. Histopathological changes in the gastrointestinal tract due to drugs: an update for the surgical pathologist (part I of II). Int J Surg Pathol 2014;22(2):120-128.

46. Ewing D, Brozovich A, Burns E, et al. Gastric Siderosis and Ulceration from Intravenous Iron Supplementation Manifesting as Chronic Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature. Case Rep Gastrointest Med 2019;2019 : 1790686.

47. Marginean EC, Bennick M, Cyczk J et al. Gastric siderosis: patterns and significance. Am J Surg Pathol 2006;30(4):514-520.

48. Tun KM, Naga Y, Mesgun S et al. Gastric Siderosis Due to Oral Ferrous Sulfate Supplements. ACG Case Rep J 2022;9(10):e00870.

49. Kaye P, Abdulla K, Wood J, et al. Iron-induced mucosal pathology of the upper gastrointestinal tract: a common finding in patients on oral iron therapy. Histopathology 2008;53(3):311-317.

50. Olave MC, Manrai P, Nalbantoglu I et al. Push pin induced artifact: A mimic of iron pill injury in gastrointestinal pathology. Hum Patho. 2026; 173 : 106119.

51. Matsukuma K, Gui D, Olson KA et al. OsmoPrep-associated Gastritis: A Histopathologic Mimic of Iron Pill Gastritis and Mucosal Calcinosis. Am J Surg Pathol 2016;40(11):1550-1556.

52. Lynch DA, Dixon MF, Axon AT. Diagnostic criteria in lymphocytic gastritis. Gastroenterology. 1997;112(4):1426-1427. Lynch DA, Dixon MF, Axon AT. Diagnostic criteria in lymphocytic gastritis. Gastroenterology 1997;112(4):1426-1427.

53. Yip RHL, Lee LH, Lee LH et al. Topography, morphology, and etiology of lymphocytic gastritis: a single institution experience. Virchows Arch 2020;476(4):551-559.

54. Arnason T, Brown IS, Goldsmith JD, et al. Collagenous gastritis: a morphologic and immunohistochemical study of 40 patients. Mod Pathol 2015;28(4):533-544.

55. Simas D, Gonçalves AR, Gomes P et al. Olmesartan-Induced Gastropathy: An Important Cause to Think about in Refractory Peptic Ulcer Disease. GE Port J Gastroenterol 2024;32(4):288-292.

56. Storozuk T, Brown I, Lagana S, et al. The histological spectrum of ARB-induced gastritis. Histopathology 2022;81(5):653-660.

57. Li J, Tanager K, Setia N. Collagenous gastritis: clinical features, histologic correlates and unanswered questions. Histopathology 2025;87(6):789-801.

58. Makino M, Kawaguchi K, Shimojo H et al. Extensive lanthanum deposition in the gastric mucosa: the first histopathological report. Pathol Int 2015;65(1):33-37.

59. Tatsuta T, Mikami T, Chinda D, et al. Case report of lanthanum deposition in the esophagus. Clin J Gastroenterol 2020;13(5):683-687.

60. Rothenberg ME, Araya H, Longacre TA, Pasricha PJ. Lanthanum-Induced Gastrointestinal Histiocytosis. ACG Case Rep J 2015;2(3):187-189.

61. Iwamuro M, Urata H, Tanaka T, Okada H. Review of the diagnosis of gastrointestinal lanthanum deposition. World J Gastroenterol 2020;26(13):1439-1449.

62. Song YJ, Liu HX, Yang XG. The deposition of lanthanum carbonate may activate macrophages to induce gastrointestinal mucosal injury in patients with chronic kidney disease: an in vitro caco-2/THP-1 macrophage coculture model study. J Biol Inorg Chem 2024;29(1):101 -⁠ 112.

63. Iwamuro M, Urata H, Tanaka T, et al. Lanthanum deposition corresponds to white lesions in the stomach. Pathol Res Pract 2018;214(7):934-939.

64. Yabuki K, Shiba E, Harada H, et al. Lanthanum deposition in the gastrointestinal mucosa and regional lymph nodes in dialysis patients: Analysis of surgically excised specimens and review of the literature. Pathol Res Pract 2016;212(10):919-926.

65. Fujimoto D, Miyagi A, Tamura U, et al. Early gastric cancer with lanthanum deposition mucosa by endoscopic submucosal dissection: a case report and literature review. Clin J Gastroenterol 2021;14(5):1344-1349.

66. Hirose K, Saito S, Oshiro Y, et al. Novel case of laparoscopically resected gastric adenocarcinoma concurrent with lanthanum deposition. Clin Case Rep 2022;10(12):e6497.

67. Hoda RS, Sanyal S, Abraham JL, et al. Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract. Histopathology 2017;70(7):1072-1078.

68. Iwamuro M, Urata H, Iwasa S et al. A Novel Method for Detecting Lanthanum Phosphate Deposition in the Gastroduodenal Mucosa Using Fluorescence Microscopy. Cureus 2022;14(10):e30729.

69. Nishida S, Ota K, Hattori K, et al. Investigation of the clinical significance and pathological features of lanthanum deposition in the gastric mucosa. BMC Gastroenterol 2020;20(1):396.

70. Greenson JK, Trinidad SB, Pfeil SA, et al. Gastric mucosal calcinosis. Calcified aluminum phosphate deposits secondary to aluminum-containing antacids or sucralfate therapy in organ transplant patients. Am J Surg Pathol 1993;17(1):45-50.

71. Gorospe M, Fadare O. Gastric mucosal calcinosis: clinicopathologic considerations. Adv Anat Pathol 2007;14(3):224-228.

72. Carneiro F, Chaves P., Ensari A. Eds: Pathology of the Gastrointestinal Tract, Springer 2017

73. Hamdeh S, Micic D, Hanauer S. Review article: drug-induced small bowel injury. Aliment Pharmacol Ther 2021;54(11-12):1370-1388.

74. Scarpignato C, Bjarnason I. Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. Curr Gastroenterol Rep 2019;21(11):55.

75. Kamboj AK, Oxentenko AS. Clinical and Histologic Mimickers of Celiac Disease. Clin Transl Gastroenterol 2017;8(8):e114.

76. Kirmizi A, Kalkan C, Yuksel S, et al. Discriminant value of IEL counts and distribution pattern through the spectrum of gluten sensitivity: a simple diagnostic approach. Virchows Arch 2018;473(5):551-558.

77. Popp A, Taavela J, Graziano P, et al. A New Intraepithelial γδ T-Lymphocyte Marker for Celiac Disease Classification in Formalin-Fixed Paraffin-Embedded (FFPE) Duodenal Biopsies. Dig Dis Sci 2021;66(10):3352-3358.

78. Maglio M, Marano A, Mandile R, et al. Immunohistochemistry to Highlight Intraepithelial Lymphocytes in Formalin-Fixed and Frozen Duodenal Biopsies: Comparability of Results and Cut-Off Revision. Dig Dis Sci 2025;70(10):3425-3431.

79. Kozan EN, Kırmızı BA, Kirsaclioglu CT, et al. A new algorithm for coeliac disease based on the ‚long forgotten‘ TCRγδ+ intra-epithelial lymphocytes detected with an antibody working on FFPE sections. Histopathology 2025;86(3):397-409.

80. Scialom S, Malamut G, Meresse B, et al. Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy. PLoS One 2015;10(6):e0125024.

81. Yilmaz F, Atay K. FOXP3 expression in duodenal mucosa: Unique role in pathogenesis and differential diagnosis of celiac disease. Ann Diagn Pathol 2025;74 : 152393.

82. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012;87(8):732-738.

83. Cyrany J, Vasatko T, Machac J et al. Letter: telmisartan-associated enteropathy -⁠ is there any class effect?. Aliment Pharmacol Ther 2014;40(5):569-570.

84. Marietta EV, Cartee A, Rishi A, Murray JA. Drug-induced enteropathy.  Dig Dis 2015;33(2):215-220.

85. Ianiro G, Bibbò S, Montalto M et al. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 2014;40(1):16-23.

86. Costetti M, Schiepatti A, Fraticelli S, et al. Clinical and gastro-duodenal histopathological features of enteropathy due to angiotensin II receptor blockers. Dig Liver Dis 2021;53(10):1262-1267.

87. Burbure N, Lebwohl B, Arguelles-Grande C et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol 2016;50 : 127-134.

88. Choi EY, McKenna BJ. Olmesartan-Associated Enteropathy: A Review of Clinical and Histologic Findings.  Arch Pathol Lab Med 2015;139(10):1242-1247.

89. Schiepatti A, Minerba P, Puricelli M, et al. Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers. Aliment Pharmacol Ther 2024;59(4):432-444.

90. Kosaka S, Kamiyama M, Ochi M. Olmesartan-induced gastritis with no lower gastrointestinal symptoms: A case report. DEN Open 2025;6(1):e70124.

91. Djembissi Fotso A, Arvanitakis M, Salame M et al. What do we know today about drug-induced microscopic colitis? A case of lymphocytic colitis on olmesartan. Acta Gastroenterol Belg 2023;86(3):474-480.

92. Gallivan C, Brown I. Olmesartan induced enterocolitis. Pathology 2014;46(4):360-361.

93. Hamdeh S, Micic D, Hanauer S. Drug-Induced Colitis. Clin Gastroenterol Hepatol 2021;19(9):1759-1779.

94. Marginean EC. The Ever-Changing Landscape of Drug-Induced Injury of the Lower Gastrointestinal Tract. Arch Pathol Lab Med 2016;140(8):748-758.

95. Herlihy N, Feakins R. Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?. United European Gastroenterol J 2022;10(5):451-464.

96. Patil DT, Odze RD. Biopsy diagnosis of colitis: an algorithmic approach. Virchows Arch 2018;472(1):67-80.

97. Fabián O, Kamaradová K. Histopathological diagnosis of colitis: differential diagnosis and interpretation. Histopatologická diagnostika kolitid: diferenciálně-diagnostický přístup a interpretace. Cesk Patol 2022;58(1):11-26.

98. Star KV, Ho VT, Wang HH, Odze RD. Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. Am J Surg Pathol 2013;37(9):1319 -⁠ 1328.

99. Washington K, Jagasia M. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum Pathol 2009;40(7):909-917.

100. Lin J, Fan R, Zhao Z, Cummings OW, Chen S. Is the presence of 6 or fewer crypt apoptotic bodies sufficient for diagnosis of graft versus host disease? A decade of experience at a single institution. Am J Surg Pathol 2013;37(4):539-547.

101. Mostafa M, Hartley CP, Hagen CE. Evaluation of the lower histologic threshold for gastric graft versus host disease. Mod Pathol 2020;33(5):962-970.

102. Myerson D, Steinbach G, Gooley TA, Shulman HM. Graft-versus-Host Disease of the Gut: A Histologic Activity Grading System and Validation. Biol Blood Marrow Transplant 2017;23(9):1573-1579. 103. Rowan DJ, Hartley CP, Carrillo-Polanco LF et al. Diagnostic phrasing is independently correlated with the decision to treat for graft -⁠ -versus-host disease: retrospective review of colon biopsies with rare apoptosis. Histopathology 2016;69(5):802-811.

104. Kuş Öztürk S, Kırmızı A, Aras N, et al. Patterns and Grading of Gastrointestinal Graft-Versus-Host Disease: A Clinicopathologic Correlation Study. Turk J Gastroenterol 2023;34(5):516-524.

105. Hippe K, Kreft A, Reu-Hofer S, et al. Round-Robin test for the histological diagnosis of acute colonic Graft-versus-Host disease validating established histological criteria and grading systems. Virchows Arch 2023;483(1):47-58.

106. Shulman HM, Cardona DM, Greenson JK, et al. NIH Consensus development project on criteria for clinical trials in chronic graft -⁠ -versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 2015;21(4):589-603.

107. Karamchandani DM, Chetty R. Apoptotic colopathy: a pragmatic approach to diagnosis. J Clin Pathol 2018;71(12):1033-1040.

108. Chlumská A, Benes Z, Mukensnabl P, Zámecník M. Histologic findings after sodium phosphate bowel preparation for colonoscopy. Diagnostic pitfalls of colonoscopic biopsies. Cesk Patol 2010;46(2):37-41.

109. Kotolová H, Nováková J. Nejvýznamnější nežádoucí účinky neopioidních analgetik a jejich farmakologické mechanismy Neurol praxi 2020; 21(6): 485–490

110. Sohail R, Mathew M, Patel KK, et al. Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review. Cureus 2023;15(4):e37080.

111. Tai FWD, McAlindon ME. Non-steroidal anti -⁠ -inflammatory drugs and the gastrointestinal tract. Clin Med (Lond) 2021;21(2):131-134.

112. Bjarnason I, Scarpignato C, Holmgren E et al. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology 2018;154(3):500-514.

113. Kei M, Uesawa Y. Comprehensive Analysis of Gastrointestinal Injury Induced by Nonsteroidal Anti-Inflammatory Drugs Using Data from FDA Adverse Event Reporting System Database. Pharmaceuticals (Basel) 2025;18(8):1204.

114. Frezza M, Gorji N, Melato M. The histopathology of non-steroidal anti-inflammatory drug induced gastroduodenal damage: correlation with Helicobacter pylori, ulcers, and haemorrhagic events. J Clin Pathol 2001;54(7):521-525.

115. Stolte M, Panayiotou S, Schmitz J. Can NSAID/ASA-induced erosions of the gastric mucosa be identified at histology?. Pathol Res Pract 1999;195(3):137-142.

116. Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case -⁠ -control study. Pharmacoepidemiol Drug Saf 2017;26(10):1141-1148.

117. Lauwers GY, Fasano A, Brown IS. Duodenal lymphocytosis with no or minimal enteropathy: much ado about nothing?. Mod Pathol 2015;28 Suppl 1:S22-S29.

118. Mekontso JG, Olliverrie A, Pendyala N, et al. Nonsteroidal Anti-Inflammatory Drug-Induced Granulomatous Colitis: A Case Report and Literature Review of a Vanishing Colonic Mass Mimicking Malignancy. Case Rep Gastrointest Med 2025;2025 : 1169139.

119. Saleem N, Marella HK, Ali B, Tombazzi CR. Colonic diaphragm disease secondary to nonsteroidal anti-inflammatory drug use. Proc (Bayl Univ Med Cent) 2020;33(3):391-392.

120. Mazhuppel Rechard E, Al-Talib I et al. The Silent Obstruction: A Rare Complication of Non-steroidal Anti-inflammatory Drug (NSAID)-Induced Diaphragm Disease. Cureus 2025;17(11):e96275.

121. Kwak HA, Hart J. The Many Faces of Medication-Related Injury in the Gastrointestinal Tract. Surg Pathol Clin 2017;10(4):887-908.

122. Medlicott SA, Ma M, Misra T, Dupre MP. Vascular wall degeneration in doxycycline-related esophagitis. Am J Surg Pathol 2013;37(7):1114-1115.

123. Xiao SY, Zhao L, Hart J, Semrad CE. Gastric mucosal necrosis with vascular degeneration induced by doxycycline. Am J Surg Pathol 2013;37(2):259-263.

124. Shih AR, Lauwers GY, Mattia A et al. Vascular Injury Characterizes Doxycycline-induced Upper Gastrointestinal Tract Mucosal Injury. Am J Surg Pathol 2017;41(3):374-381.

125. Hong Y, Staniorski C, Pollack D, Evans S. Doxycycline-Induced Gastric Perforation. Am Surg 2023;89(11):4926-4928.

126. Affolter K, Samowitz W, Boynton K, Kelly ED. Doxycycline-induced gastrointestinal injury. Hum Pathol 2017;66 : 212-215.

127. Arnold MA, Swanson BJ, Crowder CD, et al. Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. Am J Surg Pathol 2014;38(11):1530-1537.

128. Swanson BJ, Limketkai BN, Liu TC, et al. Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury.  Am J Surg Pathol 2013;37(11):1686 -⁠ 1693.

129. Karamchandani DM, Hammad H, Chetty R, Arnold CA. New Kids on the Block. Arch Pathol Lab Med 2021;145(12):1569-1584.

130. Ooishi M, Yamada S, Itoh T, et al. Diagnosis of Ion-Exchange Resin Depositions in Paraffin Sections Using Corrective Light and Electron Microscopy-NanoSuit Method. Diagnostics (Basel) 2021;11(7):1193.

131. Harel Z, Harel S, Shah PS et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.  Am J Med 2013;126(3):264.e9-264. e2.64E24.

132. Shakeri H, Panarelli NC. Patterns of gastrointestinal injury in patients with chronic kidney disease: Comparison of cases with and without sevelamer crystals. Histopathology 2024;84(4):624-632. 133. Goutorbe P, Montcriol A, Lacroix G et al. Intestinal Necrosis Associated with Orally Administered Calcium Polystyrene Sulfonate Without Sorbitol.  Ann Pharmacother 2011;45(2):e13.

134. Yuste C, Mérida E, Hernández E, et al. Gastrointestinal complications induced by sevelamer crystals. Clin Kidney J 2017;10(4):539-544.

135. Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol 2008;32(9):1367-1372.

136. Nguyen T, Park JY, Scudiere JR, Montgomery E. Mycophenolic acid (cellcept and myofortic) induced injury of the upper GI tract. Am J Surg Pathol 2009;33(9):1355-1363.

137. Lee S, de Boer WB, Subramaniam K, Kumarasinghe MP. Pointers and pitfalls of mycophenolate-associated colitis. J Clin Pathol 2013;66(1):8-11.

138. Karamchandani DM, Westbrook L, Arnold CA. Drug-induced digestive tract injury: decoding some invisible offenders. Hum Pathol 2023;132 : 135-148.

139. Liapis G, Boletis J, Skalioti C, et al. Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis. Histopathology 2013;63(5):649-658.

140. Kurnatowska I, Banasiak M, Daniel P, Wagrowska-Danilewicz M, Nowicki M. Two cases of severe de novo colitis in kidney transplant recipients after conversion to prolonged-release tacrolimus. Transpl Int 2010;23(5):553 -⁠ 558.

141. Hissong E, Mostyka M, Yantiss RK. Histologic Features of Tacrolimus-induced Colonic Injury. Am J Surg Pathol 2022;46(1):118-123.

142. Xia R, Zhang X. Neutropenic enterocolitis: A clinico-pathological review. World J Gastrointest Pathophysiol 2019;10(3):36-41.

143. Inga EE, Badireddy M. Neutropenic Enterocolitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 8, 2023.

144. Iacobuzio-Donahue CA, Lee EL, Abraham SC et al. Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. Am J Surg Pathol 2001;25(8):1067-1073.

145. Torbenson M, Montgomery EA, Iacobuzio-Donahue C et al. Colchicine effect in a colonic hyperplastic polyp. A lesion mimicking serrated adenoma. Arch Pathol Lab Med 2002;126(5):615-617.

146. Daniels JA, Gibson MK, Xu L, et al. Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. Am J Surg Pathol 2008;32(3):473-477.

147. Kiss I et al. Modrá kniha České onkologické společnosti (32. aktualizace): 2026 https:// www.linkos.cz/lekar-a-multidisciplinarni -⁠ -tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy

148. Murro D, Jakate S. Radiation esophagitis. Arch Pathol Lab Med 2015;139(6):827-830.

149. Wu Q, Li Q, Zhang R, et al. Research progress of radiation esophagitis: A narrative review. Medicine (Baltimore) 2025;104(19):e42273

150. Nesheiwat Z, Akbar H, Kahloon A, Mahajan K. Radiation Esophagitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 23, 2023.

151. Cunningham S, Singla M, Itzkowitz S. Esophageal mucosal bridge in a young man with radiation esophagitis. Gastrointest Endosc 2015;82(6):1121.

152. Birkness-Gartman JE, Hutchings DA, Montgomery EA, Voltaggio L. Injury patterns and potential diagnostic pitfalls associated with radiation and radio-chemotherapy in the stomach and gastroesophageal junction. Hum Pathol 2023;131 : 17-25.

153. Bhutta BS, Fatima R, Aziz M. Radiation Enteritis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 17, 2023.

154. Feely M, Tondon R, Gubbiotti M, et al. Gastrointestinal Tract Injury by Yttrium-90 Appears Largely Restricted to Resin Microspheres But Can Occur Years After Embolization. Am J Surg Pathol 2022;46(9):1234-1240.

155. Ogawa F, Mino-Kenudson M, Shimizu M, et al. Gastroduodenitis associated with yttrium 90-microsphere selective internal radiation: an iatrogenic complication in need of recognition. Arch Pathol Lab Med 2008;132(11):1734 -⁠ 1738.

156. Reggiani Bonetti L, Leoncini G, Daperno M, et al. Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD Group. Dig Liver Dis 2021;53(8):950-957.

157. Leupin N, Curschmann J, Kranzbühler H, et al. Acute radiation colitis in patients treated with short-term preoperative radiotherapy for rectal cancer. Am J Surg Pathol 2002;26(4):498-504.

158. Wang YT, Zhu YX, Huang RY, et al. Pathological classification of chronic radiation-induced intestinal injury and its clinical implications. Gastroenterol Rep (Oxf) 2025;13:goaf072.

159. Patil PA, Zhang X. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Arch Pathol Lab Med 2021;145(5):571-582.

160. Vaddepally RK, Kharel P, Pandey R, et al. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel) 2020;12(3):738.

161. Rajha E, Chaftari P, Kamal M, et al. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterol Rep (Oxf) 2019;8(1):25-30.

162. Auch LAM, Sieber C, Lehnick D, Hug BL. Adverse drug events of immune checkpoint inhibitors -⁠ a retrospective, descriptive real-world data analysis. BMC Cancer 2025;25(1):1303.

163. Jayathilaka B, Mian F, Franchini F, et al. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer 2025;132(1):51-57.

164. Zhang ML, Deshpande V. Histopathology of Gastrointestinal Immune-related Adverse Events: A Practical Review for the Practicing Pathologist. Am J Surg Pathol 2022;46(1):e15-e26.

165. Carbonnel F, Martin A, Marthey L, et al. Gastrointestinal complications of immune checkpoint Inhibitor therapy. Presse Med 2026;55(2):104326.

166. Arora K, Zhang LM, Goiburú-Chenu MB, et al. Pathology of immune checkpoint inhibitor-induced injury of the gastrointestinal tract and hepatobiliary systém. Diagn Histopathol 2021; 27 (2): 62-68 167. Zhang ML, Neyaz A, Patil D, et al. Immune -⁠ -related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathol 2020;76(2):233 -⁠ 243.

168. Amin S, Munankami S, Desai P, et al. Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis. Cureus 2023;15(6):e39920.

169. Boike J, Dejulio T. Severe Esophagitis and Gastritis from Nivolumab Therapy. ACG Case Rep J 2017;4:e57.

170. Haryal A, Townsend MJ, Baskaran V, et al. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer 2023;129(3):367-375. 171. Irshaid L, Robert ME, Zhang X. Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Arch Pathol Lab Med 2021;145(2):191-200.

172. Badran YR, Shih A, Leet D, et al. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer 2020;8(1):e000958.

173. Isidro RA, Ruan AB, Gannarapu S, et al. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology 2021;78(4):532-541. 174. Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases 2019;7(4):405-418.

175. Terlato M, Dimovski S, Burkhardt M et al. Drug-induced inflammatory colitis: a review of novel agents. npj Gut Liver 2026;3 : 12

176. Louie CY, DiMaio MA, Matsukuma KE et al. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides. Am J Surg Pathol 2015;39(12):1653-1660.

177. Yeung CC, Hockenbery DM, Westerhoff M, et al. Pathological assessment of gastrointestinal biopsies from patients with idelalisib -⁠ -associated diarrhea and colitis. Future Oncol 2018;14(22):2265-2277.

178. Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated Colitis: Histologic Findings in 14 Patients. Am J Surg Pathol 2015;39(12):1661-1667.

179. Hammami MB, Al-Taee A, Meeks M, et al. Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease. Clin J Gastroenterol 2017;10(2):142-146.

180. Karimi SS, Larman TC, Jain T, Voltaggio L, Birkness-Gartman JE. Chimeric antigen receptor (CAR) T-cell therapy-related gastrointestinal toxicity: Histologic features and morphologic mimics. Hum Pathol 2025;158 : 105791.

181. Osnis L, Hart J, Olivas A, et al. Patterns of Gastrointestinal Injury Associated With CAR-T Therapy for Patients With Multiple Myeloma. Am J Surg Pathol 2026;50(3):292-300.

182. Baroudi I, Abukhiran I, Pai R, Mansour A. Histopathologic Features of Chimeric Antigen Receptor (CAR) T-cell Therapy-associated Gastrointestinal Mucosal Injury: A Case Series and Review of Literature. Am J Surg Pathol 2026;50(7):739-757.

183. Ortiz Requena D, Montgomery EA, Ronquillo NR et al. Multiple Myeloma and Mimicry: Gastrointestinal Tract Histologic Findings in Patients Following Chimeric Antigen Receptor T-cell Therapy and Anti -⁠ -CD38 Monoclonal Antibodies. Mod Pathol 2026;39(5):100991.

184. Ortiz Requena D, Montgomery EA. What‘s new in upper gastrointestinal pathology: Key updates and evolving challenges in 2026. Hum Pathol 2026;169 : 106025.

185. Liu C, Amin R, Shatila M, et al. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J Cancer Res Clin Oncol 2023;149(7):3965-3976.

186. Grillo F, Carlin L, Remo A, et al. Dasatinib-induced Crohn‘s-like colitis. J Clin Pathol 2023;76(3):202-205.

187. Yamauchi K, Inaba T, Colvin HS, et al. Dasatinib-induced colitis: clinical, endoscopic and histological findings. Scand J Gastroenterol 2022;57(4):449-456.

188. Tolaymat S, Sharma K, Kagzi Y, Sriwastava S. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review. Mult Scler Relat Disord 2023;75 : 104763.

189. Kmeid M, Aldyab M, Brar R, Lee H. Histologic Findings and Tissue B-Cell Depletion in Endoscopic Mucosal Biopsy Specimens of the Gastrointestinal Tract After Treatment With Rituximab. Am J Clin Pathol 2022;157(3):353 -⁠ 364.

190. Jafari P, Hakimian D, Westerhoff M, et al. The Histologic Spectrum of Rituximab -⁠ -Associated Common Variable Immunodeficiency-Like Enteropathy. Mod Pathol 2025;38(8):100770.

191. Hakimian D, Micic D, Alpert L et al. Common Variable Immunodeficiency-Like Enteropathy Associated with Rituximab B-Cell Depletion Therapy. Dig Dis Sci 2025;70(3):996-999.

192. Hutchings D, Miller JA, Voltaggio L. Paradoxical gastrointestinal reactions in patients taking tumor necrosis factor inhibitors: a rare event that broadens the histologic spectrum of medication-associated injury. Hum Pathol 2019;85 : 202-209.

193. Mihai IR, Burlui AM, Rezus II, et al. Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment-A Review. Life (Basel) 2023;13(8):1779.

194. Huynh S, Achalu S, Berry R, et al. Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors. Dig Dis Sci 2024;69(5):1602-1607.

195. Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front Pharmacol 2023; 14 : 1124628.

196. Obeidat AE, Murakami TT. New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?. Cureus 2021;13(7):e16147.

197. Gandu SSK, Khan MH, Vasikaran A, Pandit S. Secukinumab-Induced Lymphocytic Colitis. J Investig Med High Impact Case Rep 2022;10 : 23247096221110399.

198. Sykaras AG, Margellou E, Vallianou NG, et al. Multifaceted Secukinumab-induced Colitis. Inflamm Bowel Dis 2022;28(4):e47-e48.

199. Kwan E, Riley CA, Iqbal M, Hardin CA. Malakoplakia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 30, 2026.

200. Zhang Y, Byrnes K, Lam-Himlin D, et al. Gastrointestinal Malakoplakia: Clinicopathologic Analysis of 26 Cases. Am J Surg Pathol 2020;44(9):1251-1258.

201. Lee M, Ko HM, Rubino A et al. Malakoplakia of the gastrointestinal tract: clinicopathologic analysis of 23 cases. Diagn Pathol 2020;15(1):97.

202. Alshatti Y, Alenezi M. Malakoplakia Associated with Diarrhoea and Colonic Lesions After Rituximab Treatment. Eur J Case Rep Intern Med 2024;11(12):005067.

Labels
Anatomical pathology Forensic medical examiner Toxicology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#